JP2012500264A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500264A5
JP2012500264A5 JP2011523833A JP2011523833A JP2012500264A5 JP 2012500264 A5 JP2012500264 A5 JP 2012500264A5 JP 2011523833 A JP2011523833 A JP 2011523833A JP 2011523833 A JP2011523833 A JP 2011523833A JP 2012500264 A5 JP2012500264 A5 JP 2012500264A5
Authority
JP
Japan
Prior art keywords
composition according
treating
condition
neurodegeneration
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011523833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500264A (ja
JP5773870B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040766 external-priority patent/WO2010021766A1/en
Publication of JP2012500264A publication Critical patent/JP2012500264A/ja
Publication of JP2012500264A5 publication Critical patent/JP2012500264A5/ja
Application granted granted Critical
Publication of JP5773870B2 publication Critical patent/JP5773870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011523833A 2008-08-21 2009-04-16 ヒドロキシ酪酸エステル及びその医学的使用 Active JP5773870B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9075108P 2008-08-21 2008-08-21
US61/090,751 2008-08-21
PCT/US2009/040766 WO2010021766A1 (en) 2008-08-21 2009-04-16 Hydroxybutyrate ester and medical use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014241939A Division JP6092836B2 (ja) 2008-08-21 2014-11-28 ヒドロキシ酪酸エステル及びその医学的使用

Publications (3)

Publication Number Publication Date
JP2012500264A JP2012500264A (ja) 2012-01-05
JP2012500264A5 true JP2012500264A5 (enExample) 2012-06-07
JP5773870B2 JP5773870B2 (ja) 2015-09-02

Family

ID=40885956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011523833A Active JP5773870B2 (ja) 2008-08-21 2009-04-16 ヒドロキシ酪酸エステル及びその医学的使用
JP2014241939A Active JP6092836B2 (ja) 2008-08-21 2014-11-28 ヒドロキシ酪酸エステル及びその医学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014241939A Active JP6092836B2 (ja) 2008-08-21 2014-11-28 ヒドロキシ酪酸エステル及びその医学的使用

Country Status (10)

Country Link
EP (3) EP4011374A1 (enExample)
JP (2) JP5773870B2 (enExample)
CN (1) CN102164884B (enExample)
AU (1) AU2009283171B2 (enExample)
CA (1) CA2734720C (enExample)
DK (2) DK2328858T3 (enExample)
ES (2) ES2655367T3 (enExample)
NO (1) NO2328858T3 (enExample)
PL (2) PL2328858T3 (enExample)
WO (1) WO2010021766A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2527940C (en) 2003-06-03 2016-03-22 Richard L. Veech Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
TR201908522T4 (tr) 2008-01-04 2019-07-22 The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
JP6883384B2 (ja) * 2012-11-05 2021-06-09 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 電離放射線による傷害から組織を防護するためのケトン体
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
CA2905225C (en) * 2013-03-14 2021-05-04 Isis Innovation Limited Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
EP3549928B1 (en) 2014-01-13 2021-09-22 University of South Florida Methods of sustaining dietary ketosis and its effects on muscle fatigue
CN103860533A (zh) * 2014-02-12 2014-06-18 新乡医学院 β羟基丁酸在治疗帕金森病中的应用
WO2015140752A1 (en) * 2014-03-19 2015-09-24 Stellenbosch University Method for treating or enhancing muscle tissue
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11173138B2 (en) * 2016-04-19 2021-11-16 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2017213999A1 (en) 2016-06-07 2017-12-14 The J. David Gladstone Institutes Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
AU2017381059B2 (en) * 2016-12-23 2023-11-30 Katholieke Universiteit Leuven 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
CN111050764A (zh) * 2017-07-21 2020-04-21 巴克老年研究所 β-羟基丁酸酯和丁二醇的S对映异构体及其使用方法
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2019147503A1 (en) 2018-01-25 2019-08-01 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
GB2572185A (en) * 2018-03-21 2019-09-25 Chain Biotechnology Ltd Pharmaceutical compositions
GB2575623B (en) * 2018-06-04 2022-10-26 Tdeltas Ltd 3-hydroxybutyrate esters for treating cancer cachexia
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
AU2019290926B2 (en) * 2018-06-21 2025-01-23 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (NAD+) precursor and at least one ketone or ketone precursor
GB2577723A (en) * 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
FI3880649T3 (fi) * 2019-01-17 2023-05-30 Ketolipix Therapeutics Gmbh Menetelmä hydroksikarboksyylihappojen polyolipohjaisten estereiden tuottamiseksi
CN109700021A (zh) * 2019-03-04 2019-05-03 清华大学 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用
MX2021013528A (es) 2019-05-10 2021-12-10 Ketoswiss Ag Cuerpos cetonicos encerrados en microesferas.
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
AU2020278825A1 (en) * 2019-05-21 2021-10-21 Société des Produits Nestlé S.A. Entre-deux-Villes 1800 Vevey Switzerland Dietary butyrate
WO2020249196A1 (de) * 2019-06-12 2020-12-17 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern, insbesondere polyglycerinestern, von hydroxycarbonsäuren
US20250197566A1 (en) * 2019-06-12 2025-06-19 Ioi Oleo Gmbh Process for preparing polyol-based esters of acyl-capped hydroxy carboxylic acids
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12396974B2 (en) 2020-03-27 2025-08-26 KetoneAid Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
WO2021231271A1 (en) * 2020-05-12 2021-11-18 Genomatica, Inc. Process of synthesizing and purifying (3r)-hydroxybutyl (3r)-hydroxybutanoate
CN116113618A (zh) * 2020-07-13 2023-05-12 Ioi油脂化学品有限责任公司 聚合羧酸的氧代丁醇酯的制备方法
JP2023543110A (ja) * 2020-07-13 2023-10-13 ケトリピックス セラポーティクス ゲーエムベーハー オキソブタノールでエステル化されたポリグリセロールエステルを製造する方法
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN113045416B (zh) * 2021-03-23 2023-08-18 南京纽邦生物科技有限公司 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
EP4373483A1 (en) 2021-07-17 2024-05-29 KetoSwiss AG Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
IT202100020441A1 (it) 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1051853B (it) * 1975-01-07 1981-05-20 Basf Ag Butandiol 1.3 3 mono 3 idros sibutirrati butandiol 1.3 1mono 3 idrossibutirrati e processi per la loro preparazione
JPH0755158B2 (ja) * 1986-10-30 1995-06-14 チッソ株式会社 光学活性エステルの製造法
BE1001209A3 (fr) * 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
EP1641444B1 (en) 2003-06-02 2016-03-23 Isis Innovation Limited Treatment of muscle fatigue
CA2527940C (en) * 2003-06-03 2016-03-22 Richard L. Veech Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
ES2338704T3 (es) * 2005-11-29 2010-05-11 Basf Se Procedimiento para la transesterificacion o para la esterificacion de cadenas laterales en polimeros.
US8452351B2 (en) * 2008-06-02 2013-05-28 Qualcomm Incorporated Methods and apparatus for saving battery power in mobile stations

Similar Documents

Publication Publication Date Title
JP2012500264A5 (enExample)
JP2020527583A5 (enExample)
WO2012088519A8 (en) Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
JP2012006970A5 (enExample)
JP5714227B2 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
EP3335710A3 (en) Use of nutritional compositions for preventing disorders
JP2009533356A5 (enExample)
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2875736B1 (en) N-Carbamoylputrescine to enhance muscle protein synthesis
IN2014KN02830A (enExample)
WO2010080756A3 (en) Harmine derivatives for reducing body weight
IN2012DN02590A (enExample)
RU2015129066A (ru) Применение bifidobacterium animalis для лечения или предотвращения набора веса и инсулинорезистентности
WO2018093238A3 (ko) 포름산 생성능이 우수한 균주를 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
UA106209C2 (en) Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid
JP2008534503A5 (enExample)
JP2012509669A5 (enExample)
JP2019062914A (ja) アンモニア代謝促進剤
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
WO2010107866A3 (en) Catecholamine derivatives for obesity and neurological disorders
WO2018093237A3 (ko) 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
EP2504006B1 (en) Compositions comprising amino acids for treating chronic obstructive pulmonary disease
JP5557243B2 (ja) 睡眠の改善剤